GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicio Therapeutics Inc (NAS:ELTX) » Definitions » ROC (Joel Greenblatt) %

Elicio Therapeutics (Elicio Therapeutics) ROC (Joel Greenblatt) % : -661.07% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Elicio Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Elicio Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -661.07%.

The historical rank and industry rank for Elicio Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

ELTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2667.08   Med: -864.29   Max: -339.22
Current: -339.22

During the past 5 years, Elicio Therapeutics's highest ROC (Joel Greenblatt) % was -339.22%. The lowest was -2667.08%. And the median was -864.29%.

ELTX's ROC (Joel Greenblatt) % is ranked worse than
50.48% of 1462 companies
in the Biotechnology industry
Industry Median: -329.055 vs ELTX: -339.22

Elicio Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Elicio Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Elicio Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicio Therapeutics ROC (Joel Greenblatt) % Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-864.29 -1,282.30 -2,667.08 -524.36 -432.73

Elicio Therapeutics Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -361.87 -347.86 -553.22 -482.97 -661.07

Competitive Comparison of Elicio Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Elicio Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicio Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's ROC (Joel Greenblatt) % falls into.



Elicio Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.454) - (6.277 + 0.694 + 1.885)
=-5.402

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.277) - (3.703 + 0.627 + 0.74)
=-2.793

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Elicio Therapeutics for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-47.164/( ( (7.28 + max(-5.402, 0)) + (6.989 + max(-2.793, 0)) )/ 2 )
=-47.164/( ( 7.28 + 6.989 )/ 2 )
=-47.164/7.1345
=-661.07 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicio Therapeutics  (NAS:ELTX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Elicio Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Elicio Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicio Therapeutics (Elicio Therapeutics) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Executives
Yekaterina Chudnovsky director C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Robert R Ruffolo director
Peter Demuth officer: Chief Scientific Officer C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Assaf Segal director C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Annette Matthies officer: Chief Business Officer ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139
Robert Connelly director, officer: CEO, President and Director 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Julian Adams director C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116
Christopher Haqq officer: See Remarks C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Carol Gail Ashe director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Brian Piekos officer: Chief Financial Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Gregory S Curhan officer: See Remarks 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Itzhak Goldberg officer: See Remarks 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
John F. Neylan officer: See Remarks 750 LEXINGTON AVENUE, NEW YORK NY 10022

Elicio Therapeutics (Elicio Therapeutics) Headlines

From GuruFocus